This article written in french by Nicholas Pereira was automatically translated using AI
The use of Winrevair, also known as sotatercept, is now authorized in Canada in combination with standard treatment for adults with group 1 and functional class II or III pulmonary arterial hypertension.
This product from the pharmaceutical company Merck is the first activin signaling inhibitor indicated for the treatment of pulmonary arterial hypertension in Canada.
It represents a new class of medication that works by improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation in patients with pulmonary arterial hypertension.
“We are excited about the prospects of a new treatment option for patients suffering from pulmonary arterial hypertension,” said Dr. John Granton, director of the pulmonary hypertension program at the University Health Network in Toronto, in a statement.
“As the mother of a daughter diagnosed with severe pulmonary arterial hypertension in 2014 at the age of 24, and as chair of the board of the Pulmonary Hypertension Association of Canada, I am well aware of the burden that this rare disease continues to place on our patients,” said Joan Paulin. “Our goal, as an organization, is now to ensure that all eligible patients, wherever they live in Canada, can access it.”
The next steps toward product accessibility include collaboration between the pan-Canadian Pharmaceutical Alliance (pCPA) and Merck Canada to begin negotiations on Winrevair so that it can be covered by participating public drug insurance plans in Canada.
The last launch of a new pharmacological treatment for pulmonary arterial hypertension in Canada was eight years ago. (N.P.)
Simple and Free
Meta (Facebook and Instagram) is blocking your Courrier Laval news, just as Google continues to obstruct it, in response to Bill C-18.
To access your news and stay connected to the source, Courrier Laval invites you to download its app. You can also subscribe to the weekly newsletter to keep reading your news for free, in real-time, with fewer ads. Don’t forget to turn on notifications and spread the word to your friends and contacts!
Apple: https://apple.co/3wsgmKE
Android: https://bit.ly/3uGPo1D
Newsletter: https://courrierlaval.com/infolettre/
